MCRB
NASDAQ · Biotechnology
Seres Therapeutics Inc
$9.00
-0.33 (-3.54%)
Open$9.23
Previous Close$9.33
Day High$9.53
Day Low$8.94
52W High$29.98
52W Low$6.53
Volume—
Avg Volume52.2K
Market Cap86.28M
P/E Ratio15.15
EPS$0.75
SectorBiotechnology
Analyst Ratings
Buy
9 analysts
Price Target
+185.9% upside
Current
$9.00
$9.00
Target
$25.73
$25.73
$18.91
$25.73 avg
$33.51
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 823.9K | 2.90M | 47.44M |
| Net Income | 5.94M | 18.85M | 5.52M |
| Profit Margin | 721.9% | 685.8% | 11.6% |
| EBITDA | 7.93M | 26.56M | 8.75M |
| Free Cash Flow | — | — | 3.59M |
| Rev Growth | -71.6% | -71.6% | +12.6% |
| Debt/Equity | — | — | 0.48 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $214.98 | -1.15% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $353.28 | +0.41% | 24.7 | 190.40B |
| GILD | Gilead Sciences Inc | $140.30 | +0.67% | 19.6 | 166.66B |
| VRTX | Vertex Pharmaceuticals Inc | $447.26 | +0.16% | 29.1 | 114.87B |
| REGN | Regeneron Pharmaceuticals | $777.25 | +0.60% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.73 | -0.65% | 139.7 | 43.84B |